Recruiting at 1 site Phase 2 Metabolic Syndrome

Metabolic Syndrome study: Oral Contraceptives vs Maltodextrin

Official title Combined Oral Contraceptive Pill and Resistance Starch

ClinicalTrials.gov ID: NCT06852365

What this study is testing

What is Oral Contraceptives, Low-Dose?

Oral Contraceptives, Low-Dose is an investigational medicine, taken by mouth, being studied as a potential treatment for metabolic syndrome.

Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
This study is testing whether a special fiber improves heart and blood sugar health. It also looks at how this fiber changes gut bacteria.
Who it's for
You may be able to join if you are a woman with polycystic ovary syndrome (PCOS).
What's involved
You would take birth control pills for the whole time. You would also take a fiber supplement or a pretend pill for 12 weeks.
Time commitment
The study lasts 12 weeks and includes regular check-ins.
  • Phase 2: a mid-size study of how well it works
  • You might receive a placebo (an inactive treatment) instead of the study drug.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 to 40, women only

You may be able to join if

  • Women between ages of 18-40 years with BMI greater than or equal to 25 kg/m² to less than or equal to 48 kg/m² diagnosed with PCOS defined by the...
  • For women with more regular bleeding patterns, but who are suspected to be experiencing periodic anovulatory bleeding, a midluteal progesterone (P4)...
  • Women with only hyperandrogenic PCOS phenotype (hyperandrogenism + one more criteria) will be included to decrease the heterogeneity of the cohort...
  • people should be willing to avoid pregnancy for the entire duration of the study.

You likely can't join if

  • people with other causes for irregular menses such as pregnancy, lactation, untreated hypothyroidism, untreated hyperprolactinemia and premature...
  • people with late onset adrenal hyperplasia
  • people with history of bariatric surgery
  • Those who are unable to comply with the study procedures, for instance due to mental illness, substance abuse, or participation in other studies.
  • people taking medications that affect weight or metabolic parameters (e.g. lipid lowering medications).
  • History of Crohn's disease and ulcerative colitis as well as current use of probiotics and laxatives are excluded.
See the full eligibility criteria
Who can join
  • Women between ages of 18-40 years with BMI greater than or equal to 25 kg/m² to less than or equal to 48 kg/m² diagnosed with PCOS defined by the Rotterdam criteria based on a history of chronic anovulation (8 or fewer...
  • For women with more regular bleeding patterns, but who are suspected to be experiencing periodic anovulatory bleeding, a midluteal progesterone (P4) level less than 3ng/dL will be evidence of ovulatory dysfunction and...
  • Women with only hyperandrogenic PCOS phenotype (hyperandrogenism + one more criteria) will be included to decrease the heterogeneity of the cohort and as metabolic risks are increased in these women compared to...
  • people should be willing to avoid pregnancy for the entire duration of the study.
What rules you out
  • people with other causes for irregular menses such as pregnancy, lactation, untreated hypothyroidism, untreated hyperprolactinemia and premature menopause.
  • people with late onset adrenal hyperplasia
  • people with history of bariatric surgery
  • Those who are unable to comply with the study procedures, for instance due to mental illness, substance abuse, or participation in other studies.
  • people taking medications that affect weight or metabolic parameters (e.g. lipid lowering medications).
  • History of Crohn's disease and ulcerative colitis as well as current use of probiotics and laxatives are excluded.
  • people could not have taken antibiotics for at least 3 months prior to randomization visit.
  • people with greater than 20 g/day of dietary fiber intake based on pre-screening ASA-24 survey will be excluded.
  • Type 1 or 2 diabetes
  • liver disease or dysfunctional liver (AST/ALT greater than 2x normal or a total bilirubin greater than 2.5 mg/dL)
  • renal disease (BUN greater than 30 mg/dL or serum creatinine greater than 1.4 mg/dL)
  • severe anemia (hemoglobin less than 10 mg/dL)
  • alcohol abuse
  • poorly controlled hypertension
  • TG greater than 250 mg/dl
  • chronic inflammatory conditions such as psoriasis
  • history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; known heart disease (New York Heart Association Class II or higher)
  • history of cervical carcinoma, endometrial carcinoma, or breast carcinoma, adrenal or ovarian tumor secreting androgens, and Cushing's syndrome -

The study team makes the final eligibility decision.

Where it is enrolling

  • Philadelphia, Pennsylvania, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling female, 18 years to 40 years. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.